AN2 Therapeutics reports 100% parasite elimination in NHP study; Phase 2 for Chagas planned late 2026

AN2 Therapeutics, Inc.

28-day AN2-502998 treatment in NHPs with chronic T. cruzi infection achieved 100% parasite elimination at human-target exposures, durable for 4 months post-treatment.
Phase 1 FIH study (NCT07024589) in healthy volunteers showed favorable safety, no dose-limiting toxicities, and PK exposures at NHP efficacy thresholds.
Chagas disease affects ~300k in U.S. and ~10M globally; no FDA-approved treatments for adults with chronic disease.
Company plans to initiate Phase 2 proof-of-concept study late 2026; AN2-502998 eligible for FDA Tropical Disease Priority Review Voucher if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.